Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The life study Academic Article uri icon

Overview

MeSH Major

  • Antihypertensive Agents
  • Atenolol
  • Hypertension
  • Hypertrophy, Left Ventricular
  • Losartan

abstract

  • Results of the subanalysis are sufficient to generate the hypothesis that black patients with hypertension and LVH might not respond as favorably to losartan-based treatment as non-black patients with respect to cardiovascular outcomes, and do not support a recommendation for losartan as a first-line treatment for this purpose. The subanalysis is limited by the relatively small number of events.

publication date

  • March 17, 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.jacc.2003.11.029

PubMed ID

  • 15028365

Additional Document Info

start page

  • 1047

end page

  • 55

volume

  • 43

number

  • 6